NeoPrediX - Investor Relations US

INVESTOR RELATIONS

Please contact us anytime: This email address is being protected from spambots. You need JavaScript enabled to view it.

Predictive Neonatal Clinical Decicion Support Platform

Why invest in NeoPrediX?

Software-as-a-Service
Digital Health
Breakthrough prediction tool
Global market potential
Dedicated team of scientific and market experts

Investor Calender

NeoPrediX will present at the following conferences

Investor Media Center

Introduction to NeoPrediX B.1 (Youtube)

Demo of NeoPrediX B.1 (Youtube)

Thorsten Waloschek Presents NeoPrediX at LSI USA ’23 (Youtube)

Mayo Clinic Platform_Accelerate: NeoPrediX (external link to Youtube)

PRESS RELEASES

COVERAGE BY COMPANYGLANCE

Coverage on NeoPrediX by companyglance.com

Coverage on NeoPrediX by companyglance.com: NeoPrediX: Revolutionizing Maternal And Neonatal Care With Predictive Analytics (Published: Sep 16, 2024)

Investment from Springhood Ventures

NeoPrediX Secures Investment from Springhood Ventures to Advance Neonatal Health Innovations

Fort Lauderdale, FL - NeoPrediX, a leading predictive analytics company focused on neonatal, maternal, and perinatal health, is pleased to announce an investment from Springhood Ventures. This investment will further accelerate the development and deployment of NeoPredix's innovative solutions aimed at improving outcomes for newborns worldwide.

Multi-Center Observational Study

Clinical Decision Support Company NeoPrediX AG Completes Prospective Multi-Center Observational Study

Basel, Switzerland, Regensburg, Germany, and Ft. Lauderdale, FL, USA, May 25, 2022 – NeoPrediX AG, a privately held maternal and neonatal clinical decision support company focused on the development and commercialization of intelligent algorithms to predict dynamic progression of disease parameters during the first 1,000 days of life, announced at a poster presentation during the recent 48th Annual Meeting of the German Society for Neonatology and Pediatric Intensive Medicine held in Aachen, Germany, that a prospective multi-center observational study was formally completed.

NeoPrediX PRESENT AT BIOTECH SHOWCASE™ 2022

Breakthrough Prediction Software Platform of NeoPrediX shown at BIOTECH SHOWCASE

Regensburg, Germany. 22nd of December 2021 – NeoPrediX today announced that it will be presenting virtually at the Biotech Showcase™ 2022 conference with an online presentation.

Start-up company opens first US office

NeoPrediX starts marketing its prediction software platform in USA

November 15, 2021 - With the establishment of NeoPrediX USA in Fort Lauderdale (Florida) the German/Swiss NeoPredix AG starts its US business and pushes its internationalization strategy. The start-up company develops prediction software for hospitals and neonatal units based on scientific and clinical data as well as science-based algorithms.

Who is NeoPrediX

NeoPrediX AG test is a Swiss company located in Basel with subsidiaries in Regensburg, Germany and Ft. Lauderdale, Florida, USA.

Contact us

Please feel free to contact us at any time for further questions and requests.
This email address is being protected from spambots. You need JavaScript enabled to view it.